NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68001-0425-35 | 68001-0425 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jul 7, 2020 | Aug 11, 2021 | No Longer Used |
00069-0075-01 | 00069-0075 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug 29, 2012 | Dec 31, 2016 | No Longer Used |
55150-0355-01 | 55150-0355 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 11, 2022 | In Use | |
63323-0193-52 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 1, 2009 | In Use | |
45963-0614-55 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Mar 12, 2015 | In Use | |
55150-0352-01 | 55150-0352 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb 11, 2020 | In Use | |
58468-0030-02 | 58468-0030 | Thyrotropin Alfa | Thyrogen | 0.9 mg/mL | Hormonal Therapy | Thyroid Stimulating Hormone | Intramuscular | Nov 30, 1998 | In Use | ||
58468-1849-04 | 58468-1849 | Thyrotropin Alfa | Thyrogen | Hormonal Therapy | Thyroid Stimulating Hormone | Nov 30, 1998 | May 30, 2019 | No Longer Used | |||
55513-0079-01 | 55513-0079 | Talimogene Laherparepvec | Imlygic | 100000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
55513-0078-01 | 55513-0078 | Talimogene Laherparepvec | Imlygic | 1000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
55513-0059-01 | 55513-0059 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 1.0 mg/1 | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | May 16, 2024 | In Use | |
80446-0401-01 | 80446-0401 | TEBENTAFUSP | KIMMTRAK | 100.0 ug/.5mL | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | Intravenous | Jan 26, 2022 | In Use | |
57894-0469-01 | 57894-0469 | Talquetamab | TALVEY | 3.0 mg/1.5mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
55513-0077-01 | 55513-0077 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 10.0 mg/14ml | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | Jun 12, 2024 | In Use | |
57894-0470-01 | 57894-0470 | Talquetamab | TALVEY | 40.0 mg/mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
83205-0001-02 | 83205-0001 | Afamitresgene autoleucel | TECELRA | 10000000000.0 1/1 | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | Intravenous | Aug 2, 2024 | In Use | |
25021-0467-05 | 25021-0467 | Octreotide acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
25021-0455-05 | 25021-0455 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec 15, 2013 | Feb 29, 2020 | In Use | |
00078-0181-01 | 00078-0181 | Octreotide Acetate | Sandostatin | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct 21, 1988 | In Use | ||
62756-0352-40 | 62756-0352 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 14, 2007 | Jan 31, 2017 | No Longer Used | |
00703-3301-04 | 00703-3301 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov 14, 2005 | In Use | ||
62756-0349-44 | 62756-0349 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 14, 2007 | Nov 30, 2016 | No Longer Used | |
62756-0350-40 | 62756-0350 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 14, 2007 | Jan 31, 2017 | No Longer Used | |
00781-3166-95 | 00781-3166 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb 4, 2014 | In Use | ||
69097-0880-67 | 69097-0880 | Lanreotide acetate | Lanreotide Acetate | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec 24, 2021 | In Use |
Found 11465 results — Export these results